51. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania
- Author
-
Guillaume Compaoré, Eusebio Macete, Pete Smith, Salim Abdulla, Abena Yawson, Seth Owusu-Agyei, Gabriel Leonard Upunda, Abraham Oduro, Esperança Sevene, Martin Adjuik, Rita Baiden, Fred Binka, Bernhards Ogutu, Abdunoor Mulokozi, Margaret Gyapong, Ali Sié, Alex Adjei, Isaac Osei, Raymond Akparibo, Tinto Halidou, and Innocent Valea
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Cohort event monitoring ,Safety monitoring ,QT interval ,Cohort Studies ,Antimalarials ,Young Adult ,Dihydroartemisinin/piperaquine ,Heart Conduction System ,medicine ,Humans ,Longitudinal Studies ,Prospective Studies ,Artemisinin ,Child ,Adverse effect ,Prospective cohort study ,Aged ,Aged, 80 and over ,business.industry ,Research ,Eurartesim® ,Infant, Newborn ,Infant ,Middle Aged ,medicine.disease ,Artemisinins ,Electrocardiogram ,Malaria ,Drug Combinations ,Infectious Diseases ,Child, Preschool ,Africa ,Cohort ,Quinolines ,Female ,Parasitology ,Health Facilities ,QTc prolongation ,business ,medicine.drug ,Cohort study - Abstract
Background The World Health Organization recommends artemisinin-based combination (ACT) for the treatment of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/benefit profile in malaria endemic countries. The clinical safety of the newly registered combination, Eurartesim®, following its introduction into the public health system in four African countries was assessed. Methods This was a prospective, observational, open-label, non-comparative, longitudinal, multi-centre study using cohort event monitoring. Patients with confirmed malaria had their first dose observed and instructed on how to take the second and the third doses at home. Patients were contacted on day 5 ± 2 to assess adherence and adverse events (AEs). Spontaneous reporting of AEs was continued till day 28. A nested cohort who completed full treatment course had repeated electrocardiogram (ECG) measurements to assess effect on QTc interval. Results A total of 10,925 uncomplicated malaria patients were treated with Eurartesim®. Most patients,95% (10,359/10,925), did not report any adverse event following at least one dose of Eurartesim®. A total of 797 adverse events were reported. The most frequently reported, by system organ classification, were infections and infestations (3. 24%) and gastrointestinal disorders (1. 37%). In the nested cohort, no patient had QTcF > 500 ms prior to day 3 pre-dose 3. Three patients had QTcF > 500 ms (509 ms, 501 ms, 538 ms) three to four hours after intake of the last dose. All the QTcF values in the three patients had returned to
- Published
- 2015